| Ivaltinostat | A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma | Phase 2 | Active not recruiting | 70 | Jun 2026 |
| rituximab | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia | Phase 2 | Terminated | 53 | May 5, 2026 |
| Valganciclovir | ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION | Phase 2 | Completed | 20 | Apr 1, 2026 |
| S65487 and azacitidine | Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia | Phase 2 | Completed | 57 | Mar 27, 2026 |
| Abiraterone Acetate | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer | Phase 2 | Terminated | 7 | Mar 12, 2026 |
| Tolcapone | COMT Inhibition Among Individuals With Comorbid AUD/ADHD | Phase 2 | Completed | 23 | Mar 9, 2026 |
| Azacitidine | Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Phase 2 | Completed | 121 | Jan 20, 2026 |
| Pramipexole | Long-term Efficacy of Pramipexole in Anhedonic Depression | Phase 3 | Completed | 55 | Dec 5, 2025 |
| rituximab | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation | Phase 2 | Terminated · results | 15 | Oct 13, 2025 |
| Estradiol | Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy | Phase 2 | Terminated · results | 93 | Aug 21, 2025 |
| Rivaroxaban 15 MG Oral Tablet [Xarelto] | Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion | Phase 3 | Terminated | 930 | Jun 26, 2025 |
| Pramipexole | Pramipexole for Anhedonic Depression | Phase 3 | Completed | 85 | Jun 4, 2025 |
| Cyclophosphamide | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | Phase 2 | Completed · results | 84 | Apr 1, 2025 |
| Azacitidine | Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | Phase 2 | Terminated · results | 110 | Mar 25, 2025 |
| Azacitidine and Venetoclax | Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML | Phase 2 | Completed · results | 42 | Jan 29, 2025 |
| Triamcinolone Acetonide | Symptom Clusters in Children With Exacerbation-prone Asthma | Phase 2 | Completed · results | 68 | Jan 16, 2025 |
| Azacitidine | Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | Phase 2 | Completed | 113 | Nov 30, 2024 |
| Imatinib | Trial of Imatinib for Hospitalized Adults With COVID-19 | Phase 3 | Terminated · results | 21 | Jun 30, 2024 |
| — | IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study | Phase 2 | Completed | 31 | Aug 31, 2023 |
| Capecitabine | Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer | Phase 3 | Completed | 263 | Aug 25, 2023 |
| Trastuzumab deruxtecan | DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | Phase 3 | Completed · results | 608 | Jun 30, 2022 |
| rituximab | Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | Phase 2 | Completed · results | 13 | Feb 9, 2020 |
| DUAL | New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C | Phase 2 | Completed · results | — | Not stated |
| Sirolimus | Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency | Phase 3 | Terminated | — | Not stated |